BMS scores tumour-agnostic nod for Augtyro across NTRK fusion cancersNTRK fusion cancers
13 Jun 2024
Priority ReviewDrug ApprovalAcquisitionClinical ResultAccelerated Approval
Bristol Myers Squibb's Augtyro (repotrectinib) has secured an accelerated approval from the FDA for the treatment of adult and paediatric patients aged 12 years and older with solid tumours harbouring NTRK gene fusions.
The decision announced Thursday marks the drug's second indication after gaining US approval for ROS1-positive non-small-cell lung cancer (NSCLC)ROS1-positive non-small-cell lung cancer (NSCLC) last November. Chinese regulators recently cleared the drug in this indication as well.
The broader US label is specifically for patients with NTRK fusion-positive cancerNTRK fusion-positive cancer that is locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, and who have progressed following treatment or have no satisfactory alternative therapy.
The filing, which was assessed under a priority review, was based on data from the Phase I/II single-arm TRIDENT-1 trial that evaluated Augtyro in 88 adult patients with locally advanced or metastatic NTRK gene fusion-positive solid tumours. The study included patients who had either received a prior TRK tyrosine kinase inhibitor (TKI)TRK tyrosine kinase inhibitor (TKI) or were TKI-naïve.
Augtyro demonstrated a confirmed overall response rate (ORR) of 58% among TKI-naïve patients and 50% in the TKI-pretreated group. Additionally, the duration of response was not estimable in the TKI-naïve arm and was 9.9 months among those who had previously been treated with a TKI.
Augtyro made its way into Bristol Myers Squibb's oncology portfolio through its $4.1-billion acquisition of Turning Point Therapeutics in 2022.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.